MAIA Biotechnology, Inc., ("MAIA" or the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today published a 2025 Shareholder Letter by CEO Vlad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback